Scarica l'app Stockscreener
3.69
1.65%
0.06
Pre-mercato:
3.71
0.02
+0.54%
Precedente Chiudi:
$3.63
Aprire:
$3.63
Volume 24 ore:
67,597
Relative Volume:
1.07
Capitalizzazione di mercato:
$5.69M
Reddito:
$2.54M
Utile/perdita netta:
$-4.13M
Rapporto P/E:
-1.3418
EPS:
-2.75
Flusso di cassa netto:
$-4.11M
1 W Prestazione:
-3.70%
1M Prestazione:
+34.67%
6M Prestazione:
-12.97%
1 anno Prestazione:
-11.08%
Intervallo 1D:
$3.6101
$3.77
Intervallo di 1 settimana:
$3.49
$4.1383
Portata 52W:
$2.20
$5.2683
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Nome
Xenetic Biosciences Inc
Settore
Industria
Telefono
781-778-7720
Indirizzo
945 CONCORD ST., FRAMINGHAM, MA
Confronta XBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
3.69 | 5.91M | 2.54M | -4.13M | -4.11M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-01-08 | Iniziato | Maxim Group | Buy |
Xenetic Biosciences Inc Borsa (XBIO) Ultime notizie
Why Xenetic Biosciences Inc. stock attracts strong analyst attentionLow Risk High Reward Picks - Newser
What makes Xenetic Biosciences Inc. stock price move sharplyFree Exclusive Investment Tips - Newser
How Xenetic Biosciences Inc. stock performs during market volatilityFree Signals Group - Newser
Xenetic Biosciences (NASDAQ:XBIO) Shares Down 8% – What’s Next? - Defense World
Head to Head Comparison: Xenetic Biosciences (NASDAQ:XBIO) versus Vaxart (NASDAQ:VXRT) - Defense World
Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic C - Great Falls Tribune
New to The Street Announces Media Coverage of BitMine Immersion Technologies Inc., Including NewsOut Video PR Integration - Great Falls Tribune
North Shore Uranium Engages Investing News Network - Great Falls Tribune
LQR House Announces Strategic Marketing Cooperation with Montauk Distilling Co. for Cinnamon Flavored Rum - Great Falls Tribune
Monogram Technologies Announces the Mandatory Conversion of 8.00% Series D Convertible Cumulative Preferred Stock - Great Falls Tribune
Groundbreaking Pancreatic Cancer Trial Launches: DNase I Combined With FOLFIRINOX in Advanced Cases - Stock Titan
Unusual Machines Inc. Promotes Stacy Wright to Executive Vice President of Revenue as Company Scales U.S. Footprint and Prepares for Accelerated Growth - Great Falls Tribune
Why Did Cyclacel Pharmaceuticals Inc. (CYCC) Soar 13.92%? - AInvest
Xenetic Biosciences Reports Improved Q1 2025 Results - TipRanks
Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update - Defense World
Canaccord Genuity Group Issues Pessimistic Forecast for Annovis Bio (NYSE:ANVS) Stock Price - Defense World
Head-To-Head Survey: Xenetic Biosciences (NASDAQ:XBIO) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Equities Analysts Set Expectations for XBIO Q2 Earnings - Defense World
Xenetic Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Xenetic (XBIO) Reports Strong Revenue Growth for Q1 | XBIO Stock News - GuruFocus
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial R - GuruFocus
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - ACCESS Newswire
Xenetic Reports 16% Revenue Growth, Expands Cancer Drug Development with New Clinical Partnerships - Stock Titan
Xenetic Biosciences 2025 Q1 Earnings Loss Reduction as Net Income Improves by 24.4% - AInvest
Xenetic Biosciences: Q1 Earnings Snapshot - The Washington Post
Renaissance Technologies LLC Acquires 9,700 Shares of Xenetic Biosciences Inc (NASDAQ:XBIO) - Defense World
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma - Barchart.com
Xenetic Biosciences Inc expected to post a loss of 72 cents a shareEarnings Preview - TradingView
Xenetic Biosciences, Inc. Announces Executive Leadership Transition - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Xenetic Biosciences (XBIO) to Release Earnings on Thursday - Defense World
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - ACCESS Newswire
Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update - ACCESS Newswire
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform - ACCESS Newswire
Xenetic Biosciences Inc Azioni (XBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):